Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
12 Health Care Stocks Moving In Thursday's Intraday Session
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15